R&D Trends

AstraZeneca in A5 alliance for Alzheimer’s

Friday, July 13, 2012 03:14 PM

AstraZeneca and Dr. Steven Paul of Weill Cornell Medical College have announced a first of its kind research alliance that brings four leading academic research laboratories together with AstraZeneca to study a major risk factor for Alzheimer's disease, the apolipoprotein E4 genotype (ApoE).

More... »

AHAF awards 22 grants for innovative Alzheimer’s research

Thursday, July 12, 2012 02:34 PM

The American Health Assistance Foundation (AHAF), a nonprofit organization that funds ground-breaking, early-stage research on Alzheimer’s disease, has awarded 22 new research grants, totaling more than $3.6 million, to scientists on the cutting edge of discoveries about the disease that affects over five million Americans.

More... »

Study: U.S. provides faster access to oncology drugs than Europe

Thursday, July 12, 2012 11:01 AM

Cancer patients in the U.S. get faster access to more oncology drugs to treat their disease than patients in Europe, according to a recent study by the Boston-based Tufts Center for the Study of Drug Development.

More... »

Janssen buys exclusive access to Evotec's insulin-producing beta cells

Tuesday, July 10, 2012 04:25 PM

Evotec, a drug discovery alliance and development partnership company, has licensed a portfolio of small molecules and biologics designed to trigger the regeneration of insulin-producing beta cells to Janssen Pharmaceuticals.

More... »

Abbott, ChemDiv Research ink Russian R&D collaborations

Tuesday, July 10, 2012 03:30 PM

Abbott Laboratories, a global healthcare company, and ChemDiv Research Institute (CDRI), the research entity of ChemRar Hi-Tech Centre, have signed an agreement to launch several R&D projects in Russia.

More... »

MIT nutrient mixture improves memory in early Alzheimer’s

Tuesday, July 10, 2012 10:04 AM

An MIT clinical trial of an Alzheimer’s disease treatment has found that the nutrient cocktail can improve memory in patients with early Alzheimer’s. The results confirm and expand the findings of an earlier trial of the nutritional supplement, which is designed to promote new connections between brain cells.

More... »

Prosonix, Imperial College London collaborate on engineered combo respiratory meds

Thursday, July 5, 2012 02:43 PM

Prosonix, a speciality pharmaceutical company of Oxford, U.K., has signed a collaborative research agreement with Imperial College London to accelerate the development of engineered multi-component particles (MCPs) as respiratory medicines.

More... »

Concern as NHS spending on advanced medicines to decline

Tuesday, July 3, 2012 02:29 PM

A new forecast by the Office of Health Economics, for the ABPI, has shown that total National Health Service (NHS) spending on medicines is well under control, while expenditure on innovative branded medicines is actually set to shrink in real terms and as a proportion of the healthcare budget over the next three years.

More... »

BMS acquires Amylin Pharmaceuticals, expands diabetes alliance with AZ

Monday, July 2, 2012 09:59 AM

Global biopharmaceutical company Bristol-Myers Squibb (BMS) has agreed to acquire Amylin Pharmaceuticals of San Diego for $31.00 per share in cash, pursuant to a cash tender offer and second step merger, or an aggregate purchase price of approximately $5.3 billion.

More... »

Biogen Idec, Isis partner on antisense program targeting myotonic dystrophy

Friday, June 29, 2012 03:12 PM

Weston, Mass.-based Biogen Idec and Isis Pharmaceuticals of Carlsbad, Calif., have entered into an exclusive, worldwide option and collaboration agreement to develop and commercialize a novel antisense drug for the treatment of myotonic dystrophy type 1 (DM1), also known as Steinert disease.

More... »